 Leap Therapeutics Inc NASDAQ: LPTX will present updated data from the DisTinGuish Phase 2a study of DKN-01, in combination with tislelizumab in gastric or gastric gastroesophageal junction cancer GGEJ. Data will be shared at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. 